Unknown

Dataset Information

0

Osimertinib plus Ramucirumab: The Best of Both Worlds?


ABSTRACT: Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced EGFR mutation-positive non-small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation-positive patients. The accompanying article reports on a study combining osimertinib with ramucirumab.See related article by Yu et al., p. 992.

SUBMITTER: Garon EB 

PROVIDER: S-EPMC7887048 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9520008 | biostudies-literature
| S-EPMC7172977 | biostudies-literature
| S-EPMC6503136 | biostudies-literature
| S-EPMC10788952 | biostudies-literature
| S-EPMC4777975 | biostudies-literature
| S-EPMC1635131 | biostudies-other
| S-EPMC4068864 | biostudies-literature
| S-EPMC8965822 | biostudies-literature
| S-EPMC8491157 | biostudies-literature
| S-EPMC8312739 | biostudies-literature